Article in Antimicrobial agents and chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 5 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors at 4 institutions in 2 countries.
Masaaki ToyamaDivision of Antiviral Chemotherapy, Joint Research Center for Human Retrovirus Infection, Kagoshima Universitygrid.258333.c, Kagoshima, Japan.
Koichi WatashiDepartment of Virology II, National Institute of Infectious Diseases, Tokyo, Japan.
Masanori IkedaDivision of Biological Information Technology, Joint Research Center for Human Retrovirus Infection, Kagoshima Universitygrid.258333.c, Kagoshima, Japan.
Atsuya YamashitaDepartment of Microbiology, Division of Medical Sciences, Graduate School of Interdisciplinary Research, University of Yamanashigrid.267500.6, Chuo, Yamanashi, Japan.
Mika OkamotoDivision of Antiviral Chemotherapy, Joint Research Center for Human Retrovirus Infection, Kagoshima Universitygrid.258333.c, Kagoshima, Japan.
Kohji MoriishiDepartment of Microbiology, Division of Medical Sciences, Graduate School of Interdisciplinary Research, University of Yamanashigrid.267500.6, Chuo, Yamanashi, Japan.ORCID 0000-0002-9542-5188
Masamichi MuramatsuDepartment of Virology II, National Institute of Infectious Diseases, Tokyo, Japan.ORCID 0000-0002-0153-3533
Takaji WakitaDepartment of Virology II, National Institute of Infectious Diseases, Tokyo, Japan.
Ashoke SharonDepartment of Chemistry, Birla Institute of Technology, Mesra, Ranchi, India.
Masanori BabaDivision of Antiviral Chemotherapy, Joint Research Center for Human Retrovirus Infection, Kagoshima Universitygrid.258333.c, Kagoshima, Japan.ORCID 0000-0002-6109-5248
Kagoshima University · JPNational Institute of Infectious Diseases · JPUniversity of Yamanashi · JPBirla Institute of Technology, Mesra · IN
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Novel neplanocin A derivatives have been identified as potent and selective inhibitors of hepatitis B virus (HBV) replication
Indexed as
Hepatitis BHepatitis B virusAdenosineAntiviral AgentsDNA, ViralHumansRNAVirus ReplicationAdenosineAntiviral AgentsDNA, Viralneplanocin ARNAantiviralhepatitis B virusneplanosin A derivativeunique mechanism
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Novel Neplanocin A Derivatives as Selective Inhibitors of Hepatitis B Virus with a Unique Mechanism of Action. · full record | OpenQuestion